LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 513 | 9649 | 10473 | 0.9213 | 0.9624 |
MCF 10A | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 513 | 9281 | 10473 | 0.8862 | 0.9452 |
MCF 10A | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 513 | 8668 | 10473 | 0.8277 | 0.9149 |
MCF 10A | XMD11-85h | 10 | uM | LJP6 | 72 | hr | 513 | 5283 | 10473 | 0.5042 | 0.7075 |
MCF 10A | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 513 | 8960 | 10362 | 0.8647 | 0.9340 |
MCF 10A | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 513 | 2848 | 10362 | 0.2748 | 0.4846 |
MCF 10A | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 513 | 1414 | 10362 | 0.1366 | 0.2632 |
MCF 10A | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 513 | 1303 | 10362 | 0.1257 | 0.2389 |
MCF 10A | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 513 | 1297 | 10362 | 0.1253 | 0.2376 |
MCF 10A | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 513 | 649 | 10362 | 0.0626 | 0.0534 |
MCF 10A | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 513 | 9926 | 10362 | 0.9578 | 0.9801 |
MCF 10A | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 513 | 8611 | 10362 | 0.8311 | 0.9164 |
MCF 10A | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 513 | 2357 | 10362 | 0.2273 | 0.4198 |
MCF 10A | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 513 | 626 | 10362 | 0.0604 | 0.0466 |
MCF 10A | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 513 | 667 | 10362 | 0.0643 | 0.0619 |
MCF 10A | Erlotinib | 10 | uM | LJP5 | 72 | hr | 513 | 773 | 10362 | 0.0746 | 0.0985 |
MCF 10A | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 513 | 7067 | 10473 | 0.6749 | 0.8271 |
MCF 10A | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 513 | 2719 | 10473 | 0.2597 | 0.4630 |
MCF 10A | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 513 | 1020 | 10473 | 0.0974 | 0.1708 |
MCF 10A | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 513 | 863 | 10473 | 0.0824 | 0.1266 |
MCF 10A | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 513 | 786 | 10473 | 0.0751 | 0.1014 |
MCF 10A | Gefitinib | 10 | uM | LJP6 | 72 | hr | 513 | 824 | 10473 | 0.0787 | 0.1150 |
MCF 10A | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 513 | 10927 | 10362 | 1.0548 | 1.0246 |
MCF 10A | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 513 | 10609 | 10362 | 1.0239 | 1.0109 |
MCF 10A | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 513 | 9986 | 10362 | 0.9639 | 0.9830 |